NIH Guide: Weekly Index for September 10, 2021

Funding Opportunities

• Making Health Care Safer in Ambulatory Care Settings and Long-term Care Facilities (R18)
  (PA-21-267)
  Agency for Healthcare Research and Quality
  Application Receipt Date(s): Standard dates apply. The first standard due date for the FOA is January 25, 2022. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Administrative Supplements to Promote Diversity in Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed)
  (PA-21-345)
  Office of the Director, NIH
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of General Medical Sciences
  National Cancer Institute
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Library of Medicine
  National Institute of Mental Health
  National Institute of Nursing Research
  National Institute of Neurological Disorders and Stroke
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Institute of Biomedical Imaging and Bioengineering
  National Center for Environmental Health
  National Center for Injury Prevention and Control
  National Institute for Occupational Safety and Health
  National Institute on Minority Health and Health Disparities
  National Center for Advancing Translational Sciences
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): Applications are accepted on a rolling basis at any time starting 30 days after the Open Date until the expiration date, unless otherwise noted in Institute specific language. Please consult with Scientific contacts listed in Section VII. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Emerging Global Leader Award (K43 Independent Clinical Trial Required)
  (PAR-21-251)
  John E. Fogarty International Center
  National Institute on Aging
  National Cancer Institute
  National Institute of Environmental Health Sciences
  National Human Genome Research Institute
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Office of Research on Women's Health
  Application Receipt Date(s): November 3, 2021, November 3, 2022, and November 3, 2023 by 5:00 PM local time of the applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
  (PAR-21-252)
  John E. Fogarty International Center
  National Institute on Aging
  National Cancer Institute
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Office of Research on Women's Health
  Application Receipt Date(s): November 3, 2021, November 3, 2022, and November 3, 2023 by 5:00 PM local time of the applicant organization. Alltypes of non-AIDS applicationsallowed for this funding opportunity announcement are due on these dates.
• NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required)
  (PAR-21-299)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applications are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Independent Clinical Trial Not Allowed)
  (PAR-21-300)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applications are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed)
  (PAR-21-301)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applications are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)
  (PAR-21-302)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applications are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)
  (PAR-21-327)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)
  (PAR-21-328)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
  (PAR-21-330)
  National Cancer Institute
  Application Receipt Date(s): October 11, 2024
• AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)
  (PAS-21-270)
  National Institute on Drug Abuse
  Application Receipt Date(s): Multiple dates, see announcement.
• Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R01 - Clinical Trial Optional)
  (RFA-DA-22-028)
  National Institute on Drug Abuse
  Application Receipt Date(s): February 9, 2022
• Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R21 - Clinical Trial Optional)
  (RFA-DA-22-039)
  National Institute on Drug Abuse
  Application Receipt Date(s): February 9, 2022
• High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
  (RFA-DA-22-040)
  National Institute on Drug Abuse
  Application Receipt Date(s): August 1, 2024
• An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immunogenicity in Severe Hemophilia A: Hemophilia A Analytical Cohort Research Program (UG3/UH3 Clinical Trial Not Allowed)
  (RFA-HL-22-004)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): October 19, 2021
• Detecting Cognitive Impairment, Including Dementia, in Primary Care and Other Everyday Clinical Settings for the General Public and Health Equity, Pragmatic Clinical Trials (U01 Clinical Trial Required)
  (RFA-NS-22-009)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): November 10, 2021
• Small Vessel VCID Biomarkers Validation Consortium Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-NS-22-017)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): November 12, 2021
• The Human BioMolecular Atlas Program (HuBMAP) Demonstration Project (U01 Clinical Trial Not Allowed)
  (RFA-RM-21-027)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): November 19, 2021